Knockdown of galectin-1 suppresses the growth and invasion of osteosarcoma cells through inhibition of the MAPK/ERK pathway

Oncology Reports

Volumn 32, Issue 4, 2014, Pages 1497-1504

  Miao, Jin Hao ^a   Wang, Shu Qiang ^a   Zhang, Ming Hui ^b   Yu, Feng Bin ^c   Zhang, Lei ^a   Yu, Zhong Xiang ^a   Kuang, Yong ^a  

^a SHUGUANG HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b HARBIN MEDICAL UNIVERSITY   (China)

^c No 98 Hospital of PLA   (China)

Author keywords

Galectin 1; Growth; Invasion; Osteosarcoma

Indexed keywords

CASPASE 3; GALECTIN 1; KI 67 ANTIGEN; LENTIVIRUS VECTOR; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; SHORT HAIRPIN RNA; GELATINASE B; LGALS1 PROTEIN, HUMAN; MMP9 PROTEIN, HUMAN; SMALL INTERFERING RNA;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CLINICAL ARTICLE; CONTROLLED STUDY; DISTANT METASTASIS; ENZYME INHIBITION; FEMALE; GAL 1 GENE; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; INTRACELLULAR SIGNALING; MALE; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TUMOR INVASION; TUMOR VOLUME; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; ANIMAL; APOPTOSIS; BONE TUMOR; CANCER TRANSPLANTATION; CELL PROLIFERATION; GENETICS; METABOLISM; METASTASIS; MOUSE; PATHOLOGY; TUMOR CELL LINE; YOUNG ADULT;

ANIMALS; APOPTOSIS; BONE NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GALECTIN 1; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; MATRIX METALLOPROTEINASE 9; MICE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; OSTEOSARCOMA; P38 MITOGEN-ACTIVATED PROTEIN KINASES; RNA, SMALL INTERFERING; YOUNG ADULT;

EID: 84911912245     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2014.3358     Document Type: Article

References (28)

1. Carrle D and Bielack SS: Current strategies of chemotherapy in osteosarcoma. Int Orthop 30: 445-451, 2006. (Pubitemid 44900550)
2. Bielack SS, Kempf-Bielack B, Delling G, et al : Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20: 776-790, 2002. (Pubitemid 34111386)
3. Tajima Y, Yamazaki K, Makino R, et al: Gastric and intestinal phenotypic marker expression in early differentiated-type tumors of the stomach: clinicopathologic significance and genetic background. Clin Cancer Res 12: 6469-6479, 2006. (Pubitemid 44799720)
4. Barrow H, Rhodes JM and Yu LG: The role of galectins in colorectal cancer progression. Int J Cancer 129: 1-8, 2011.
5. Alves PM, Godoy GP, Gomes DQ, et al: Significance of galectins-1, -3, -4 and -7 in the progression of squamous cell carcinoma of the tongue. Pathol Res Pract 207: 236-240, 2011.
6. Barrow H, Guo X, Wandall HH, et al: Serum galectin-2, -4, and -8 are greatly increased in colon and breast cancer patients and promote cancer cell adhesion to blood vascular endothelium. Clin Cancer Res 17: 7035-7046, 2011.
7. Kamper P, Ludvigsen M, Bendix K, et al: Proteomic analysis identifies galectin-1 as a predictive biomarker for relapsed/refractory disease in classical Hodgkin lymphoma. Blood 117: 6638-6649, 2011.
8. Tang CE, Tan T, Li C, et al: Identification of Galectin-1 as a novel biomarker in nasopharyngeal carcinoma by proteomic analysis. Oncol Rep 24: 495-500, 2010.
9. Espelt MV, Croci DO, Bacigalupo ML, et al: Novel roles of galectin-1 in hepatocellular carcinoma cell adhesion, polarization, and in vivo tumor growth. Hepatology 53: 2097-2106, 2011.
10. Xue X, Lu Z, Tang D, et al: Galectin-1 secreted by activated stellate cells in pancreatic ductal adenocarcinoma stroma promotes proliferation and invasion of pancreatic cancer cells: an in vitro study on the microenvironment of pancreatic ductal adenocarcinoma. Pancreas 40: 832-839, 2011.
11. Carlsson MC, Balog CI, Kilsgård O, et al: Different fractions of human serum glycoproteins bind galectin-1 or galectin-8, and their ratio may provide a refined biomarker for pathophysiological conditions in cancer and inflammatory disease. Biochim Biophys Acta 1820: 1366-1372, 2012.
12. Kuo PL, Huang MS, Cheng DE, et al: Lung cancer-derived galectin-1 enhances tumorigenic potentiation of tumor-associated dendritic cells by expressing heparin-binding EGF-like growth factor. J Biol Chem 287: 9753-9764, 2012.
13. Cedeno-Laurent F, Opperman M, Barthel SR, Kuchroo VK and Dimitroff CJ: Galectin-1 triggers an immunoregulatory signature in Th cells functionally defined by IL-10 expression. J Immunol 188: 3127-3137, 2012.
14. Gomez-Brouchet A, Mourcin F, Gourraud PA, et al: Galectin-1 is a powerful marker to distinguish chondroblastic osteosarcoma and conventional chondrosarcoma. Hum Pathol 41: 1220-1230, 2010.
15. Dhondge A, Surendran S, Seralathan MV, et al : Cellular alterations and modulation of protein expression in bitumen-challenged human osteoblast cells. Environ Sci Pollut Res Int 19: 4030-4041, 2012.
16. Wu H, Chen P, Liao R, et al: Overexpression of galectin-1 is associated with poor prognosis in human hepatocellular carcinoma following resection. J Gastroenterol Hepatol 27: 1312-1319, 2012.
17. Kim HJ, Jeon HK, Cho YJ, et al: High galectin-1 expression correlates with poor prognosis and is involved in epithelial ovarian cancer proliferation and invasion. Eur J Cancer 48: 1914-1921, 2012.
18. Wu MH, Hong HC, Hong TM, et al: Targeting galectin-1 in carcinoma-associated fibroblasts inhibits oral squamous cell carcinoma metastasis by downregulating MCP-1/CCL2 expression. Clin Cancer Res 17: 1306-1316, 2011.
19. Cedeno-Laurent F, Watanabe R, Teague JE, et al: Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma. Blood 119: 3534-3538, 2012.
20. Satelli A and Rao US: Galectin-1 is silenced by promoter hypermethylation and its re-expression induces apoptosis in human colorectal cancer cells. Cancer Lett 301: 38-46, 2011.
21. Ito K, Stannard K, Gabutero E, et al: Galectin-1 as a potent target for cancer therapy: role in the tumor microenvironment. Cancer Metastasis Rev 31: 763-778, 2012.
22. Mathieu V, de Lassalle EM, Toelen J, et al: Galectin-1 in melanoma biology and related neo-angiogenesis processes. J Invest Dermatol 132: 2245-2254, 2012.
23. Chandhanayingyong C, Kim Y, Staples JR, et al: MAPK/ERK signaling in osteosarcomas, Ewing sarcomas and chondrosarcomas: therapeutic implications and future directions. Sarcoma 2012: 404810, 2012.
24. Mirzoeva OK, Das D, Heiser LM, et al: Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 69: 565-572, 2009.
25. Roy SK, Srivastava RK and Shankar S: Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal 5: 10, 2010.
26. Chung LY, Tang SJ, Sun GH, et al: Galectin-1 promotes lung cancer progression and chemoresistance by upregulating p38 MAPK, ERK, and cyclooxygenase-2. Clin Cancer Res 18: 4037-4047, 2012.
27. Tsimaratou K, Kletsas D, Kastrinakis NG, et al: Evaluation of claspin as a proliferation marker in human cancer and normal tissues. J Pathol 211: 331-339, 2007. (Pubitemid 46172709)
28. Cawston TE and Wilson AJ: Understanding the role of tissue degrading enzymes and their inhibitors in development and disease. Best Pract Res Clin Rheumatol 20: 983-1002, 2006. (Pubitemid 44356460)